Klimedix (Drospirenone, Estradiol Hemihydrate)

Drospirenone provides progestogenic activity with anti‑mineralocorticoid and anti‑androgenic effects, while estradiol hemihydrate supplies estrogen. Together they suppress the hypothalamic release of gonadotropins, preventing the LH surge and ovulation, and they also thicken cervical mucus and alter the endometrium to block sperm passage and implantation.

The dosing regimen for Klimedix is determined by the prescribing healthcare professional. Typically, it is taken as a once‑daily tablet following the schedule indicated on the prescription label, but the exact number of tablets and cycle length are set by the prescriber based on individual patient needs.

Klimedix is contraindicated in pregnancy and is classified as pregnancy category X, meaning it must not be used by pregnant women. While limited data exist for breastfeeding, most guidelines advise against using combined oral contraceptives during lactation unless the benefits outweigh potential risks.

To order Klimedix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Klimedix contains drospirenone, which has anti‑mineralocorticoid and anti‑androgenic properties, potentially offering benefits such as reduced water retention and improved acne compared with some levonorgestrel‑based pills. However, the overall efficacy in preventing pregnancy is comparable across approved combined oral contraceptives, and safety profiles must be evaluated individually.

Klimedix tablets should be stored at ambient temperature, below 25 °C, in their original blister pack or container. Protect them from excess moisture, heat and direct sunlight. Keep the medication out of reach of children and do not use tablets that are discoloured or past the expiry date.

Klimedix is taken orally as a tablet, usually once each day at the same time, with or without food. Patients are generally instructed to follow a 28‑day cycle (21 active tablets followed by 7 placebo or hormone‑free days), but the exact schedule should follow the prescriber's directions.

The most serious risks include venous thromboembolism (deep‑vein thrombosis or pulmonary embolism), arterial thrombosis (stroke or myocardial infarction), severe hypertension, and rare severe allergic reactions such as anaphylaxis. Prompt medical attention is required if symptoms such as sudden chest pain, shortness of breath, severe headache, visual changes, or swelling of the legs occur.

Klimedix should not be used by women who are pregnant or breastfeeding, smokers over 35 years of age, or anyone with a history of thromboembolic disorders, stroke, myocardial infarction, uncontrolled hypertension, severe liver disease, known hypersensitivity to drospirenone, estradiol or any tablet excipients.